Long-acting ropivacaine pharmaceutical composition, preparation method therefor and use thereof

A long-acting ropivacaine pharmaceutical composition comprising, based on the total weight of the composition, in weight percentage,

• 0.5% to 10% of ropivacaine;
• 2% to 25% of a pharmaceutical solvent;
• 8% to 55% of a pharmaceutical phospholipid;
• 15% to 89% of a pharmaceutical oil;
• 2% to 10% of an efficacy enhancer;
• 0% to 1% of an antioxidant;
• and
• 0% to 8% of an acid-base regulator,
• wherein the efficacy enhancer is one or more selected from substances having an eicosapentaenoic acid content of no less than 15% and a docosahexaenoic acid content of no less than 10%, or the efficacy enhancer is selected from linseed oil, perilla seed oil, walnut oil, argan oil, fish oil, layer oil and algal oil, and combinations thereof,
• wherein the pharmaceutical phospholipid is one or more selected from the group consisting of natural phospholipids, semi-synthetic phospholipids and synthetic phospholipids,
• wherein the natural phospholipid is selected from the group consisting of egg yolk lecithin, soybean phospholipid and combinations thereof,
• wherein the semi-synthetic phospholipid is selected from hydrogenated egg yolk lecithin, hydrogenated soybean phospholipid and combinations thereof, and
• wherein the synthetic phospholipid is one or more selected from the group consisting of dipalmitoyl phosphatidylethanolamine, dipalmitoyl phosphatidic acid, dipalmitoylphosphatidylglycerol, dioleoylphosphatidylethanolamine, dipalmitoylphosphatidylcholine, distearoylphosphatidyl-choline, and dimyristoylphosphatidylcholine.